TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04818580

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Tension Sutures
Description: In each patient, one side of the chest will receive progressive tension sutures inside the mastectomy pocket, from pectoral fascia to underside of mastectomy flap. 2-0 Vicryl about 15-20 sutures per chest. Both sides will receive bilateral drains (standard of care)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Progressive Tension Sutures
Description: In each patient, one side of the chest will receive progressive tension sutures inside the mastectomy pocket, from pectoral fascia to underside of mastectomy flap. 2-0 Vicryl about 15-20 sutures per chest. Both sides will receive bilateral drains (standard of care)
Study: NCT05577689

Intervention type: OTHER
Intervention: Tissue
Description: Tissue will be derived from patients during a standard of care procedure
Study: NCT05829278

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu), ST36(Zusanli ), KI3 (Taixi), and etc.
Study: NCT04844749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERU-111
Description: Based on the safety and antitumor activity of VERU-111 in the Phase 1b/2 clinical study, VERU-111 is initiating this Phase 3 clinical study of VERU-111 for the treatment of metastatic castration resistant prostate cancer in patients who have failed prior treatment with at least one androgen receptor targeting agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide, Abiraterone
Description: Enzalutamide and abiraterone were chosen as active comparators are both are FDA approved for the treatment of metastatic castration resistant prostate cancer
Study: NCT05410600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm ergometer smart trainer cycling program
Description: Arm ergometer exercise training using the smart trainer.
Study: NCT05391854

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pep2dia
Description: 700 mg Pep2Dia® 15 min prior to breakfast and 700 mg Pep2Dia® 15 min prior to dinner

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 700 mg placebo 15 min prior to breakfast and 700 mg placebo 15 min prior to dinner
Study: NCT05095610

Intervention type: DEVICE
Intervention: Flash
Description: Use of the device FreeStyle Libre, only commercialized system for intermitent continuous glucose monitoring.
Study: NCT04803981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SpoonfulONE
Description: SpoonfulONE is a line of nutritional food products designed to help improve diet diversity starting in early infancy. SpoonfulONE covers a wide range of food proteins. Each product contains 30 mg of peanuts, milk, shellfish (shrimp), tree nuts (almond, cashew, hazelnut, pecan, pistachio, and walnut), egg, fish (cod and salmon), grains (wheat and oat), soy, and sesame.
Study: NCT06144840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dersimelagon
Description: MT-7117

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05830162

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: We will evaluate how many women gets an infection and/or wound dehiscence after a second degree obstetric tear or episiotomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bioclavid (Amoxicillin and Clavulanic acid)
Description: We will evaluate how many women gets an infection and/or wound dehiscence after a second degree obstetric tear or episiotomy
Study: NCT06526117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: The study intervention will include initial treatment with low-dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day), with subsequent increase to moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) after at least two severe events requiring physician contact.
Study: NCT06523530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate 3.6 mg inj, implant
Description: 3.6 mg (1ml) administered subcutaneously once every month for 6 months (totally 6 injections)
Study: NCT04943874

Intervention type: DEVICE
Group type: OTHER
Intervention: Technology Based Intervention Group 1
Description: In Phase 1, all participants will use the same technology. In Phase 2, participants will be blinded to the two specific groups. They will not be aware of the technology used in the group they are not assigned too.

Intervention type: DEVICE
Group type: OTHER
Intervention: Technology Based Intervention Group 1
Description: In Phase 1, all participants will use the same technology. In Phase 2, participants will be blinded to the two specific groups. They will not be aware of the technology used in the group they are not assigned too.

Intervention type: DEVICE
Group type: OTHER
Intervention: Technology Based Intervention Group 2
Description: Participants will be blinded to the two specific groups. They will not be aware of the technology used in the group they are not assigned too.
Study: NCT05671874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web/mobile/tablet-based digital decision aid + communication (DA+C) tool
Description: The web/mobile/tablet-based digital DA+C toll is designed to enhance communication and shared decision making between clinicians and surrogates of critically ill severe acute brain injury (SABI) with four goals: to 1) prepare families for their surrogate role and discussions with clinicians; 2) provide balanced information to families on prognosis and all available treatment options; 3) provide tailored information about the patient and family to clinicians in advance of family meetings; and 4) serve as a communication guide for clinicians in the clinician-family meeting to facilitate shared decision-making.
Study: NCT05266456

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 24 valent pneumococcal conjugate vaccine
Description: 0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 24 valent pneumococcal conjugate vaccine
Description: 0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 24 valent pneumococcal conjugate vaccine
Description: 0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
Study: NCT06265077

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: famotidine and loratadine
Description: famotidine 20 mg once daily and loratadine 10 mg once daily
Study: NCT05497440

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: All'InCath CBC 035M Balloon Dilatation Catheter
Description: All participants will undergo the same intervention. Peripheral Vasculature Percutaneous Transluminal Angioplasty and Control Angiography.
Study: NCT05266456

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 20 valent pneumococcal conjugate vaccine
Description: 0.5 ml dose of PCV20 will be administered into the deltoid muscle at Day 1
Study: NCT06354244

Intervention type: DEVICE
Intervention: Electroacupuncture of 2 sessions per week
Description: Acupoints including bilateral BL23, BL32, BL33, BL35 and SP6 are inserted with acupuncture needles(size 0.30 × 40 mm and 0.30 × 75 mm or 0.40 × 100 mm,Hwato Brand). Bilateral BL32 and BL33 are needled to a depth of 70-95 mm with an angle of 60°-75° inward and downward, into the second and third sacral foramen. Bilateral BL35 are needled to a depth of 60-70 mm in a slightly superolateral direction. Bilateral BL23 and SP6 are vertically needled to a depth of 25-30 mm. After deqi is evoked, electric stimulators with a 5Hz continuous wave (5-10 mA intensity) are separately connected to bilateral BL32, BL33,BL35 and SP6. Current intensity is adjusted according to the patients' individual tolerance. During each session, electroacupuncture(EA) is retained for 30 minutes. The patients receive EA 2 sessions per week for 2-24 weeks.EA can be terminated if the patient acquire satisfactory spontaneous urination.

Intervention type: DEVICE
Intervention: Electroacupuncture of 3 sessions per week
Description: Acupoints and electroacupuncture (EA) procedures are the same as in the group of EA of 2 sessions per week, but the patients receive EA 3 sessions per week for 2-24 weeks in this group.EA can be terminated if the patient acquire satisfactory spontaneous urination.

Intervention type: DEVICE
Intervention: Electroacupuncture of 4 sessions per week
Description: Acupoints and electroacupuncture (EA) procedures are the same as in the group of EA of 2 sessions per week, but the patients receive EA 4 sessions per week for 2-24 weeks in this group.EA can be terminated if the patient acquire satisfactory spontaneous urination.
Study: NCT06210412

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health education and yoga intervention group
Description: Health education program based on the Penderin Health Promotion Model; It consists of 10 sessions as a program focused on the management of menopause (increasing the quality of life by teaching physical, psychological and social coping methods in menopause, yoga practices and their importance). In the first week, introduction, first tests (Sociodemographic data form, MÖYKÖ), and general introduction of the program will be made. It is a program in which active education methods (question and answer, role play, demonstration, etc.) are used, with each session planned to last approximately 30 minutes. Final tests will be performed at the end of 12 weeks.~Yoga practice will be carried out as 45-minute sessions 2 days a week, which will last for 12 weeks, following the health education program.12. At the end of the week, MOQÖ and Yoga Transformation Impact Scale will be applied to those who have completed 10 weeks.
Study: NCT06463964

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Creatinine
Description: Laborataries for prediction of AKi in patients with ADHF

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Creatinine
Description: Laborataries for prediction of AKi in patients with ADHF
Study: NCT05895084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Yoga
Description: Yoga is delivered as described in an earlier section in a group format. Classes are an hour in duration and occur once per week for 8 weeks, and they are led by an adaptive yoga specialist.
Study: NCT04605562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP+DDP
Description: Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles; induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP+DDP
Description: Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles; induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP+DDP
Description: Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles; induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Administered orally

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 blocking antibody
Description: Administered every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 blocking antibody
Description: Administered every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib
Description: Administered orally
Study: NCT04790240

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inflammation (I)
Description: 1. upper respiratory inflammation (PurInf (I)): Lonicerae Flos 2.4g, Forsythiae Fructus 2.4g, Schizonepetae Herba 2g, Saposhnikoviae Radix 2g, Cicadae Periostracum 1g, Sophorae flavescentis Radix 2.4g, Atractylodis Rhizoma 2g, Angelicae dahuricae Radix 2g, Menthae haplocalycis Herba 2g, Arctii Fructus 2g, Glycyrrhizae Radix 1g~2. high fever (PurInf (II)): Bupleuri Radix 3g, Scutellariae Radix 2.4g, Gypsum fibrosum 4g, Anemarrhenae Rhizoma 3g~3. lower Respiratory system inflammation (PurInf (III)): Scutellariae Radix 2.4g, Coptidis Rhizoma 1g, Phellodendri Cortex 2.4g, Gardeniae Fructus 2.4g, Houttuyniae Herba 4g, Golden Buckwheat 3g

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inflammation (II)
Description: Platycodi Radix 2.4g, Peucedani Radix 2.4g, Cynanchi stauntonii Rhizoma 2.4g, Asteris Radix 2.4g, Stemonae Radix 2.4g, Lepidii Descurainiae Semen 2.4g, Plantaginis Semen 2.4g

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inflammation (III)
Description: 1. Metabolites, abnormal fluids (PurPhl):~   Citri reticulatae Pericarpium 1.2g, Citri grandis Exocartium rubrum 2g, Aurantii Fructus immaturu 2g, Pinelliae Rhizoma preparatum 2.4g, Arisaematis Rhizoma preparatum 2.4g, Amoni Fructus 1g, Trichosanthis Fructus 2.4g, Fritillatiae cirrhosae Bulbu 2.4g, Poria 2.4g, Rhei Radix et Rhizoma 1g~2. Capillaries circulation disorder (PurClo):~Salviae miltiorrhizae Radix 2.4g, Curcumae Radix 2.4g, Paeoniae Radix rubra 2.4g, Persicae Semen 2.4g, Carthami Flos 2.4g

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: remdesivir (Veklury), Colchicine, anti-SARS-CoV-2 monoclonal antibodies, bamlanivimab, Casirivimab \& Imdevimab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: remdesivir (Veklury), Colchicine, anti-SARS-CoV-2 monoclonal antibodies, bamlanivimab, Casirivimab \& Imdevimab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: remdesivir (Veklury), Colchicine, anti-SARS-CoV-2 monoclonal antibodies, bamlanivimab, Casirivimab \& Imdevimab.
Study: NCT05566600

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human (allogeneic) iPS-cell-derived cardiomyocyte
Description: 10-20 epicardial injections (0.25 mL each) of iPSC-CMs will be delivered in the border zone of the infarcted myocardium

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human (allogeneic) iPS-cell-derived cardiomyocyte
Description: 10-20 epicardial injections (0.25 mL each) of iPSC-CMs will be delivered in the border zone of the infarcted myocardium

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human (allogeneic) iPS-cell-derived cardiomyocyte
Description: 10-20 epicardial injections (0.25 mL each) of iPSC-CMs will be delivered in the border zone of the infarcted myocardium
Study: NCT04504487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drain Removal
Description: Abdominal drain placed during surgery removal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Drain Removal
Description: Abdominal drain placed during surgery removal
Study: NCT05099926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing Exercise Sensitivity with Exposure Training
Description: Participants complete 2, home-based intervention visits on a secure video visit platform. Video visits include psychoeducation, interoceptive exposure, and interoceptive counseling. For homework, participants are asked to document their weekly physical activity and exercise sensations in a journal.~Psychoeducation: Participants are educated about the benefits and safety of exercise and cardiac rehabilitation, the role of fear and anxiety in exercise avoidance, and the concept of interoceptive exposure.~Interoceptive Exposure: A gradual six-minute walk (G6MW) serves as a low-risk form of interoceptive exposure. Exercise sensations and ratings of perceived intensity and distress are collected before and after the G6MW.~Interoceptive Counseling: Participants review and reflect upon their pre-walking and post-walking physical sensations and ratings (intensity and distress) with a research team member. Homework is also reviewed.
Study: NCT05858385

Intervention type: OTHER
Intervention: Intervention based on key factors identified by the severe RIOM prediction model
Description: Intervention based on key factors identified by the severe RIOM prediction model
Study: NCT05334654

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin Sodium
Description: Enoxaparin will be subcutaneously administered at a dosage from 4000 to 8000 twice daily according

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Bivalirudin will be intravenously administered to obtain an activated prothrombin time (aPTT) of 1.5 fold of the normal values.
Study: NCT05448716

Intervention type: DIAGNOSTIC_TEST
Intervention: Left Atrial Strain Imaging
Description: Two-dimensional, color Doppler, spectral Doppler recordings will be taken from parasternal, apical, subcostal, and modified sections using a Philips Epiq CVx echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed with speckle tracking echocardiography from these recordings.

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiography
Description: Electrocardiography will be taken at baseline and the follow-up periods
Study: NCT05965193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normobaric Hyperoxia
Description: Within 4.5 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nasal oxygen
Description: For nasal oxygen group, Patients were immediately given oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 1L/min using nasal cannula and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous thrombolysis(rt-PA)
Description: 10% dose of rt-PA (0.9 mg/kg) is given as bolus and the rest given as an infusion over the remaining 1 hour. Maximum dose 90mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis(rt-PA)
Description: 10% dose of rt-PA (0.9 mg/kg) is given as bolus and the rest given as an infusion over the remaining 1 hour. Maximum dose 90mg.
Study: NCT05043532

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2 passes during EUS-guided fine needle biopsy
Description: Once the pancreatic mass has been visualized on endoscopic ultrasound, a total of two passes will be performed and placed in 10% formalin for processing for molecular profiling. Onsite evaluation will be performed using a part of the sample from the first pass in order to establish onsite diagnostic adequacy in all patients.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3 passes during EUS-guided fine needle biopsy
Description: Once the pancreatic mass has been visualized on endoscopic ultrasound, a total of three passes will be performed and placed in 10% formalin for processing for molecular profiling. Onsite evaluation will be performed using a part of the sample from the first pass in order to establish onsite diagnostic adequacy in all patients.
Study: NCT05720871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS + capsaicin 150μM (natural TRPV1 agonist)
Description: Repetitive transcranial magnetic stimulation (non-invasive brain stimulation) + Capsaicin.~5 consecutive days of active treatment consists of swallowing 10mL capsaicin (150μM) and, just after, of applying focal (alpha D70 coil) rTMS (Magstim Rapid2, UK) over the pharyngeal M1 hotspot of the unaffected hemisphere. A total of 500 pulses/session are delivered consisting of 10 5Hz-trains of 10s of 50 pulses each (total 2500 pulses), with a 1min interval between trains at an intensity of 90% of the resting motor threshold (RMT).~The intervention has its respective sham rTMS+placebo group that is also applied over 5 consecutive days.

Intervention type: DEVICE
Group type: OTHER
Intervention: rTMS + capsaicin 150μM (natural TRPV1 agonist)
Description: Repetitive transcranial magnetic stimulation (non-invasive brain stimulation) + Capsaicin.~5 consecutive days of active treatment consists of swallowing 10mL capsaicin (150μM) and, just after, of applying focal (alpha D70 coil) rTMS (Magstim Rapid2, UK) over the pharyngeal M1 hotspot of the unaffected hemisphere. A total of 500 pulses/session are delivered consisting of 10 5Hz-trains of 10s of 50 pulses each (total 2500 pulses), with a 1min interval between trains at an intensity of 90% of the resting motor threshold (RMT).~The intervention has its respective sham rTMS+placebo group that is also applied over 5 consecutive days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS + capsaicin 150μM (natural TRPV1 agonist)
Description: Transcranial direct current stimulation (non-invasive brain stimulation) + Capsaicin.~Treatment consists of swallowing 10mL capsaicin (150μM) and, just after, of applying 30min of 2.0mA tDCS (DC-Stimulator Plus, NeuroConn, Germany) with the anode placed over the pharyngeal primary motor cortex (M1) of the unaffected hemisphere (3.5cm lateral / 1cm anterior to the vertex) and the cathode over the opposite supraorbital region.~The intervention has its respective sham tDCS+placebo group that is also applied over 5 consecutive days.

Intervention type: DEVICE
Group type: OTHER
Intervention: tDCS + capsaicin 150μM (natural TRPV1 agonist)
Description: Transcranial direct current stimulation (non-invasive brain stimulation) + Capsaicin.~Treatment consists of swallowing 10mL capsaicin (150μM) and, just after, of applying 30min of 2.0mA tDCS (DC-Stimulator Plus, NeuroConn, Germany) with the anode placed over the pharyngeal primary motor cortex (M1) of the unaffected hemisphere (3.5cm lateral / 1cm anterior to the vertex) and the cathode over the opposite supraorbital region.~The intervention has its respective sham tDCS+placebo group that is also applied over 5 consecutive days.
Study: NCT04940754

Intervention type: PROCEDURE
Group type: OTHER
Intervention: osteosynthesis
Description: Closed reduction, internal fixation